Baeten, D., Baraliakos, X. and Braun, J. (2014) Erratum: Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Randomised, Double-Blind, Placebocontrolled Trial. The Lancet, 382, 1705-1713.
https://doi.org/10.1016/S0140-6736(13)61134-4

has been cited by the following article:

• TITLE: Overview of Research on the Treatment of Ankylosing Spondylitis in Chinese Medicine

  AUTHORS: Chen Gu, Yuefang Li

  KEYWORDS: Chinese Medicine, Ankylosing Spondylitis

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 28, 2023

  ABSTRACT: Ankylosing Spondylitis (AS), also known as spondylitis, is a rheumatic disorder that develops gradually in the sacroiliac, lumbar, thoracic and cervical spine and can involve peripheral joints in severe cases. The disease is insidious, starting in the sacroiliac and hip joints and gradually involving the entire spine. AS, also known as seronegative arthritis, is primarily due to a negative response to the susceptibility sheep blood clotting test (RF). Until the 1960s, it was known as “central rheumatoid arthritis” and “rheumatoid spondylitis”. At present, modern medicine has no effective treatment for this disease, but Chinese medicine treatment for ankylosing spondylitis is based on the concept of treating both the symptoms and the underlying cause of the disease, with few side effects and significant clinical effects, and has become a research hotspot in recent years, worthy of further investigation.